Evidence map›Paper›PMID 24903784›Full record

ReviewThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2014

How can mathematical models advance tuberculosis control in high HIV prevalence settings?

R M G J Houben, D W Dowdy, A Vassall, T Cohen, M P Nicol, R M Granich, J E Shea, P Eckhoff, C Dye, M E Kimerling and 2 more

Open access · greenAbstract readReview
In one paragraph

Review in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

R M G J HoubenTB Modelling Group, TB Centre, and Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, UK.
D W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
A VassallDepartment of Global Health and Development, LSHTM, London, UK.
T CohenCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
M P NicolDivision of Medical Microbiology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town and National Health Laboratory Service, South Africa.
R M GranichJoint United Nations Programme on HIV/AIDS, World Health Organization (WHO), Geneva, Switzerland.
J E SheaOxford-Emergent Tuberculosis Consortium, Wokingham, UK.
P EckhoffIntellectual Ventures Laboratory, Bellevue, Washington, USA.
C DyeHIV, TB Malaria and Neglected Tropical Diseases Cluster, WHO, Geneva, Switzerland.
M E KimerlingBill and Melinda Gates Foundation, Seattle, Washington, USA.
R G WhiteTB Modelling Group, TB Centre, and Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, UK.
TB MAC TB-HIV meeting participants
London School of Hygiene & Tropical Medicine · GBWorld Health Organization - Pakistan · PKBill & Melinda Gates Foundation · USCenter for Disease Dynamics, Economics & Policy · USIntellectual Ventures (United States) · USJohns Hopkins University · USUniversity of Cape Town · ZA

Funding

Wellcome Trust 091769World Health Organization 001
6 · The paper itself

Abstract

Existing approaches to tuberculosis (TB) control have been no more than partially successful in areas with high human immunodeficiency virus (HIV) prevalence. In the context of increasingly constrained resources, mathematical modelling can augment understanding and support policy for implementing those strategies that are most likely to bring public health and economic benefits. In this paper, we present an overview of past and recent contributions of TB modelling in this key area, and suggest a way forward through a modelling research agenda that supports a more effective response to the TB-HIV epidemic, based on expert discussions at a meeting convened by the TB Modelling and Analysis Consortium. The research agenda identified high-priority areas for future modelling efforts, including 1) the difficult diagnosis and high mortality of TB-HIV; 2) the high risk of disease progression; 3) TB health systems in high HIV prevalence settings; 4) uncertainty in the natural progression of TB-HIV; and 5) combined interventions for TB-HIV. Efficient and rapid progress towards completion of this modelling agenda will require co-ordination between the modelling community and key stakeholders, including advocates, health policy makers, donors and national or regional finance officials. A continuing dialogue will ensure that new results are effectively communicated and new policy-relevant questions are addressed swiftly.

Indexed as

CoinfectionModels, TheoreticalAnti-HIV AgentsAntitubercular AgentsDecision Support TechniquesEpidemicsHealth PrioritiesHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansNeeds AssessmentPrevalenceTreatment OutcomeTuberculosisAnti-HIV AgentsAntitubercular Agents

Identifiers

PMID24903784
PMCPMC4436821
OpenAlexW1981940348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.